European advisory group backs Novartis’ Isturisa and Mayzent

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Novartis’ (NYSE:NVS) Isturisa (osilodrostat) for the treatment of Cushing’s syndrome, a metabolic disorder in which the body produces excessive amounts of the hormone cortisol.

CHMP also backs Mayzent (siponimod) for the treatment of adults with secondary progressive multiple sclerosis with active disease.

A final decision from the European Commission usually takes ~60 days.

https://seekingalpha.com/news/3519697-european-advisory-group-backs-novartis-isturisa-mayzent